Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer.
39 previously treated patients with metastatic breast cancer were treated in a partially randomized study evaluating VP-16 and the combination of Vincristine (VCR) and Adriamycin (ADR). Of the 19 patients treated with VP-16 initially, two had partial remissions. No responses were noted in eleven patients who corssed-over after failing VCR plus ADR. Of the 20 patients treated with VCR plus ADR initially, four patients had partial responses. An additional 2/15 patients responded on crossover after failing initially on VP-16. No significant differences in time to last follow-up or death could be detected between the two treatment programs.
D000230:Adenocarcinoma / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012075:Remission, Spontaneous; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D011034:Podophyllotoxin